United Therapeutics (UTHR) Cost of Revenue (2009 - 2026)

United Therapeutics (UTHR) has 18 years of Cost of Revenue data on file, last reported at $133.4 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue rose 44.22% year-over-year to $133.4 million; the trailing twelve-month figure through Mar 2026 stood at $425.3 million (up 29.15% YoY), and the FY2025 full-year result was $384.4 million, up 24.12% from the prior year.
• Cost of Revenue improved to $133.4 million in Q1 2026, from $103.4 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $133.4 million in Q1 2026 to a low of $25.9 million in Q1 2022.
• A 5-year average of $72.7 million and a median of $72.9 million in 2024 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue slipped 20.16% in 2022 and jumped 115.82% in 2023, its largest moves.
• Tracing UTHR's Cost of Revenue over 5 years: stood at $58.8 million in 2022, then increased by 20.75% to $71.0 million in 2023, then gained by 6.9% to $75.9 million in 2024, then jumped by 36.23% to $103.4 million in 2025, then climbed by 29.01% to $133.4 million in 2026.
• Business Quant data shows UTHR's Cost of Revenue at $133.4 million in Q1 2026, $103.4 million in Q4 2025, and $100.9 million in Q3 2025.